7 reasons why investors dismiss Lucid Diagnostics LUCD (from least valid to most)

AI Summary

{"summary": "Author presents a bullish case for Lucid Diagnostics (LUCD), arguing EsoGuard's precancerous Barrett's esophagus test has a large TAM, settled CMS screening population, and a near-term CMS coverage catalyst that could drive reimbursement and break-even, while acknowledging management guidance errors and dilution risk.", "reason": "The author provides a fundamental investment thesis for LUCD based on market opportunity, reimbursement catalysts, and operational metrics, while acknowledging risks.", "ideas": [{"symbol": "LUCD", "direction": "long", "thesis": "Author argues Lucid Diagnostics' EsoGuard detects precancerous Barrett's esophagus, a condition missed by MCED blood tests, with a screening population already defined by CMS and a $60B TAM based on 30M patients at the $1938 CMS price. A unanimous positive CAC meeting and expected CMS coverage decision in late 2025 or early 2026 could unlock reimbursement, with break-even at only 5-6k tests per quarter. Main stated risks are management's repeated guidance errors on CMS timing and dilution risk (cash runs out Q2 2027, but $20M ATM and VA revenue from Q4 2026 should extend runway).", "thesis_short": "Long LUCD on CMS coverage catalyst and $60B TAM", "quote": "To summarize, #1-5 are pretty easy to debunk. #6-7 are legit concerns, but when you look at the size of the opportunity ($60B) and the current market capitalization ($150M), they're pretty easy to live with!", "confidence": 0.85, "sentiment": 0.8, "timeframe": "CMS decision late 2025/early 2026; cash runway Q2 2027"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}

Score 1

Comments 1

▶ Full Post Text

7 reasons why investors dismiss Lucid Diagnostics LUCD (from least valid to most)

1) They think multi-cancer early detection (MCED) blood tests cover esophageal cancer.  

These tests do detect stage 3-4 esophageal cancer with decent sensitivity (94-100%), but by then it’s too late.  EsoGuard enables a total cure by identifying a precancerous condition called Barrett’s esophagus (BE).  At this stage, sensitivity of MCEDs is <12.5%.  [Source](https://www.annalsofoncology.org/article/S0923-7534(21)02046-9/fulltext)

2) EsoGuard seems unpleasant to them.  

This has been formally studied and was published in the American Journal of Gastroenterology in 2024, first author is Dr. Helen Moinova from Case Western.  94% of people who completed the Esoguard test would recommend to family and friends, and 94% would do it again if needed (those were 2 separate questions with the same result).  [Source](https://pubmed.ncbi.nlm.nih.gov/38686933/)

3) They’re afraid CMS won’t cover Esoguard or will restrict the population.

The [foundational LCD](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39256&ver=7&=) already defines the screening population.  This wasn’t even a question at the contractor advisory committee (CAC) meeting.  The screening population is 100% settled.   

The [CAC meeting](https://www.youtube.com/watch?v=9SyCyQQz8QE&t=4857s) was high profile and unanimously positive.  There were hundreds of attendees from biotech companies, hospital systems, insurance companies, and academia. It's hard to imagine a scenario where Moldx medical directors go against the advice of their own hand picked panel.  This would be spectacularly embarrassing for Moldx.

4) They think the $60B TAM is a made up, company number. 

The $60B TAM is calculated by multiplying the size of the screening population (30M) by the established CMS price ($1938.01).  The screening population is defined by AGA and already described in the foundational LCD (see #3).  Both numbers are independent of Lucid, and capturing just 1% of the total market each year would translate to $581M in revenue.

It’s worth noting that the Concert EsoGuard list price is $2,499, so $60B may be conservative.  The screening population also has the potential to grow based on new research into patients who get esophageal cancer without ever having symptoms of GERD.

5) They are afraid of the challenges and uncertainties of launching a new product.  

Lucid is already conducting 3-4K tests every quarter.  The launch party is over.  Right now they are intentionally throttling volume until reimbursement is more solid.  They break even on only 5-6k tests per quarter, so once they are being paid, they could reach break even quickly.  

6) They don't like management.

Management has had some challenges.  When they announced that they had submitted their reconsideration request in November 2024, they guided for a CMS decision in 1H 2025.  They clearly did not understand the process.  Fast forward to fall 2025, after the CAC meeting, they guided for CMS coverage in late 2025 or early 2026.  Way off again!   

So yes, they've made some pretty serious errors in guidance.  However, Lucid still has a Harvard educated heart surgeon CEO, who is on the board of directors of AdvaMed and has testified in front of Congress.  Dr. Aklog is intelligent, well-connected, and steady at the helm. 

 7) Dilution fears 

Right now cash runs out in Q2 2027.  There will be dilution, but they have options.  There is $20M left on the ATM, and they have had no problems in the last few years doing nice clean equity offerings (no warrants, no price ratchets) although the discount has been steep.  If they elect to use the ATM, that $20M would nearly get them into Q4 2027 if revenue is flat.  However, revenue from the VA contract should start coming in Q4 2026 and throughout 2027, which will extend runway.  There is no reason to panic. 

To summarize, #1-5 are pretty easy to debunk.  #6-7 are legit concerns, but when you look at the size of the opportunity ($60B) and the current market capitalization ($150M), they're pretty easy to live with!

Not advice, do what you want with your own money.

▶ Full Post Text

Ideas

More from Reddit — r/pennystocks